TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.11) by 87.5 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $13.205 million which beat the analyst consensus estimate of $12.863 million by 2.66 percent. This is a 59.85 percent increase over sales of $8.261 million the same period last year.